11-13 October 2018 – Takis presents at NIBIT (Italian Network for Cancer Biotherapy), Milan, Italy
In recent decades, there has been a growing development of biological, immunological and pharmacological therapy in the treatment of cancer. NIBIT is the most important network in Italy covering all aspects of Cancer Biotherapy.
This year, Takis presents data on its neo-antigen cancer vaccine delivered by DNA electro-gene-transfer (DNA-EGT). Neo-antigens arising from cancer somatic mutations are a promising source of immunogens for cancer immunotherapy. At the same time, we demonstrated that DNA-EGT is a safe methodology, resulting in greater DNA cell uptake, enhanced protein expression and concomitant increase in longer-term immune responses against the target antigen.
Biotherapy represents the future of cancer treatments and we are committed to implementing a number of innovative technologies to offer new perspectives to cancer patients.